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Abstract. This article describes recent developments in the design and implementation of various 
strategies towards the development of novel therapeutics using first principles from biology and chemis-
try. Strategies for multi-target therapeutics and network analysis with a focus on cancer and HIV are dis-
cussed. Methods for gene and siRNA delivery are presented along with challenges and opportunities for 
siRNA therapeutics. Advances in protein design methodology and screening are described, with a focus 
on their application to the design of antibody based therapeutics. Future advances in this area relevant to 
vaccine design are also mentioned. 
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1. Introduction 
Over the past few decades, there have been signifi-
cant advances in the fields of chemistry, molecular, 
structural and cell biology, and genetics, which have 
led to an increased understanding of the various life 
processes in general. However, much remains to be 
explored. Rapid increases in human population, 
overcrowding, environmental degradation and rapid 
transport have all enhanced the spread of existing in-
fectious diseases as well as the threat of newly 
emerging infections. At the same time increased 
mechanization, sedentary lifestyles, dietary changes 
and an increase in life expectancy have lead to  
increased rates of a variety of non-infectious dis-
eases. Advances in diverse areas of chemistry and 
biology are being used to discover therapeutics for 
both infectious and non-infectious diseases. Novel 
strategies have been discovered to design and make 
new active principles. This article discusses a few of 
them, which appear to be promising. The article is 
divided into two parts; the first part describes pro-
gress in the area of small molecule therapeutics, 
gene delivery and siRNA technology. The next part 
describes recent progress in the area of protein 
therapeutics. 
 Organic chemistry is an enabling principle for the 
development of molecules that can selectively per-
turb or probe various biological systems. There is a 
growing understanding of the identification of mole-
cules or systems that engage in distinct interaction 
with one or several components of complex and  
dynamic biological milieu. Here we present  
instances where chemical biology principles have 
been extended for different therapeutic leads. 
2. Multi-target therapeutics and network  
analysis 
The modern drug discovery has shifted its focus 
from the concept of one gene, one drug, and one dis-
ease, i.e. single-target strategy to multitarget strat-
egy, which is based on network biology (figure 1).1,2 
Former suffers from lack of efficacy, toxicity, drug 
resistance and huge investment. Network biology is 
a tool to overcome this, which emphasizes on tack-
ling the elements that disturb the diseased network 
rather than targeting the specific gene causing the 
disease. 
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Figure 1. Drug development strategies. 
3. Strategies of multi-target therapeutics 
(a) Multiple drugs are given in combination, as in 
antiretroviral therapy for AIDS. But patient compli-
ance and adverse drug-drug interactions are the main 
drawbacks of this method. 
 (b) Multicomponent therapeutics where two or 
more active ingredients are effectively combined 
into a single delivery system and administered as a 
drug. It is easy to find the optimal formulation with 
different agents that achieve maximum potency. If 
required, the target can be subjected to differential 
exposure of the individual agents by a programmed 
release of the constituting agents. However, differ-
ences in pharmacokinetics, bioavailability and me-
tabolism of the individual ingredients cause many 
problems. Examples include, drugs e.g. Atripla 
(HIV drug), Advair (a drug for chronic obstructive 
pulmonary diseases), Caduet (used for treatment of 
high blood pressure and high cholesterol), etc. 
 For either of the above two-drug combination 
strategies, not only should the individual drug be 
safe but should be so also in combination. This lim-
its the availability of safe drug combinations. 
 (c) Individual multi-targeted single agents, which 
use the principle of polypharmacology, where a sin-
gle compound specifically binds to two or more  
molecular targets.3 Such a drug circumvents the 
problems regarding equitable pharmacokinetics and 
biodistribution. The formulation of an individual  
active agent is easier compared with that of a mix-
ture. Examples of multi target drugs are: Symbalta 
(cymbalta), Sutent (an oral multikinase inhibitor, an 
anti-cancer drug for multiple cancer), Nexavar  
(an oral multi-kinase inhibitor, an anti-cancer drug 
for liver and kidney), etc. Cymbalta is an antidepres-
sant drug belonging to serotonin and norepinephrin 
reuptake inhibitors, which works by restoring their 
balance in the brain. It is used to treat depression 
and anxiety disorder. 
 This is also used for managing pain caused by 
nerve damage in patients suffering from diabetic 
neuropathy. 
 Now to make polypharmacological drugs, one has 
to identify a lead compound which has activity 
against multiple targets without becoming nonselec-
tive and then this should be transformed into a drug 
with a good pharmaceutical profile. More challeng-
ing is to optimize the potency at both the targets. To 
predict a multi-target compound requires high level 
computational methods to explore a vast number of 
possible drug and target combinations which are 
compatible with each other. 
4. Multi-target therapeutics and network analy-
sis for cancer treatment 
Most of the current anticancer drugs have low thera-
peutic index because their action is based on inhibit-
ing the essential functions that are present in both 
normal and cancerous cells. Their effectiveness is 
because of rapidly dividing nature of the cancer cells 
compared to the normal cells. It would be ideal if 
anticancer agents target proteins or interactions that 
are essential in cancer cells but non-essential in 
normal cells. The genetic changes in a cancer cell 
change the relative dependence on specific proteins 
relative to normal cells. Thus the new methodology 
takes advantage of this difference in topology of the 
biological network to produce drugs with better 
therapeutic index. 
4.1 Drug design based on network analysis 
Effect of a drug is studied in the context of relevant 
interactions (link) present in protein, regulatory, 
metabolic or signalling networks where the respec-
tive target is called element. Analysis based on  
genomic, proteomic, metabolism, etc. are the meth-
ods to identify the systemic analysis of multitarget 
drug action. A simple topological model is created 
by suppressing an element or a link and then its  
effect on the network is studied. It is found that mul-
tiple but partial attacks on various elements or links 
is more efficient than complete attack on a single 
element or link because the former affect more 
number of network links.4 Thus, multi-target drugs 
are better than single target drugs because they  
affect more sites of network. The effect is more if 
they are distributed over the entire network. 
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4.2 Mutations in phosphatidylinositol 3-kinase –  
a cause for cancer 
Phosphatidylinositol 3-kinases/Phosphoinositide 3-
kinases (PI 3-kinases or PI3Ks) are enzymes which 
can phosphorylate the position-3 hydroxyl group of 
inositol ring of phosphatidylinositol. Discovery of 
cancer specific mutations in the catalytic subunit 
p110α of class I PI3K has made it a promising can-
cer target.5 
 The p110α mutations show a preference to three 
mutational hot spots within the coding region of 
PIK3CA. Many of the mutations in p110α due to 
cancer are missense mutations where an amino acid 
is substituted with the change in a single nucleotide. 
The p110α hot spot mutants can grow independ-
ently, resistant to apoptosis and can spread the  
tumour elsewhere.6 
 Many other rare mutations accompany p110α  
mutations with some gain of function like activating 
growth factor-independent phosphorylation of Akt 
and p70s6K and enhancing the lipid kinase activity. 
Nonetheless rare types of mutants are less efficient 
than the hot-spot mutants with respect to initiation 
or replication of the cancerous cells. 
 Based on molecular modelling, function of muta-
tions present in various functional domains is pro-
posed. Homology model proposes that the gain of 
function in p110α might involve cellular localiza-
tion, interaction with other proteins and modifica-
tion of the catalytic activity. 
4.3 Mutants in p110α as cancer targets 
The drug should be isoform specific because α-
isoform is the main regulator of the cell growth.7 
Small molecule inhibitors are good candidates  
because they can be cancer specific and PI3K being 
an enzyme can be targeted easily by them. The pres-
ence of mutational hot spots can be taken into ad-
vantage to achieve mutant specificity. It is found 
that substitution of H1047R creates most robust can-
cerous p110α with highest frequency. Now a com-
pound that can differentiate between the mutant and 
wild-type protein, thus binding with two adjacent 
sites on the target protein, can be a promising candi-
date. 
 A deeper understanding of the structure of wild-
type and mutant p110α would greatly enhance the 
identification of mutant-specific small molecule  
inhibitors and throw light on how mutant-mediated 
gain of function takes place. 
5. Challenges in the development of HIV  
medicine 
Most dreaded disease of the modern day world is 
AIDS (Acquired Immuno Deficiency Syndrome), 
which is caused by HIV-1 virus. A vaccine for HIV-
1 seems to be still elusive for the scientists because 
the virus is highly diverse in nature, and escapes the 
adaptive immune responses, difficult to induce 
broad reactive antibody responses and its viral  
reservoirs are set up very early.8 Though there are 
drugs which partially prevent the disease by control-
ling the viral replication to a certain extent, there is 
no vaccine which completely blocks the infection 
and provides full immunity. 
5.1 Life cycle of HIV 
The viral RNA and other contents enter into the  
cytoplasm of the cell after the virus attaches itself to 
specific receptors in lymphocyte membrane. The en-
zyme reverse transcriptase transcribes the viral RNA 
sequence into a complementary DNA sequence and 
the enzyme ‘integrase’ coalesces with host cell 
DNA. Replication of viral RNA is triggered by acti-
vation of lymphocyte which is followed by transla-
tion to produce various structural proteins like reverse 
transcriptase, protease, integrase, etc. Proliferation 
occurs when infected proteins bind to healthy  
immune cells.9 
6. Viral entry inhibitors 
(a) Enfuvirtide (DP-178, T-20), a peptide inhibits 
HIV fusion by preventing the fusion of a glycopro-
tein (gp41) of the viral envelope with the cell mem-
brane. This is taken along with other antiretrovirals 
but its low genetic barrier to resistance undermines 
its usefulness. 
 (b) Small molecule antagonists like mozobil, 
maraviroc, vicriviroc and aplaviroc hinder the viral 
entry by targeting human chemokine receptors 
CCR5 and CXCR4. 
6.1 HIV protease inhibitors 
HIV protease belongs to an aspartic protease family 
which plays an indispensable role in the life cycle of 
HIV. Protease inhibitors block protease activity by 
mimicking the structure of its regular substrate and 
subsequent competitive binding with the virus. 
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Some examples are atazanavir, tipranavir and darun-
avir, etc. 
6.2 HIV reverse transcriptase inhibitors 
These are of two types – nucleoside reverse tran-
scriptase inhibitors (NRTIs) and non-nucleoside  
reverse transcriptase inhibitors (NNRTIs). NRTIs 
are first converted into their active metabolites and 
then they act as competitive inhibitors or alternative 
substrates with respect to the normal substrates 
(dATP, dGTP, dCTP or dTTP) and lead to the ter-
mination of chain elongation. Some examples are 
zidovudine, didanosine, zalcitabine, etc. Nucleotide 
reverse transcriptase inhibitors (NtRTIs) also have 
similar mode of action but they differ in the number 
of steps required for their activation. 
6.3 HIV non-nucleoside reverse transcriptase  
inhibitors 
They block the enzyme’s activity by interacting with 
an allosteric binding site on HIV-1 reverse transcrip-
tase. Some examples of this category include nevi-
rapine, delavirdine, etc. 
7. Chemical interface in lipid rafts 
Stier and Sackmann postulated the concept of mem-
brane microdomains in 1970 (ref. 10) which was 
later supported and further studied in detail by vari-
ous other groups. Gerrit van Meer coined the term 
‘lipid rafts’ for these microdomains which are  
enriched with lipids, cholesterol, glycolipids and 
sphingolipids present in cell membranes.11 Although 
this concept was invoked to explain the transport of 
cholesterol from the trans golgi network to plasma 
membrane, recent research12 has shown that these 
lipid rafts have roles in diverse processes like signal 
transduction, endocytosis apart from cholesterol 
trafficking. 
 Composition of lipid rafts can be a well-ordered, 
cholesterol- and glycosphingolipid-enriched domain 
or a diverse collection of lipids, showing variable 
enrichment in cholesterol and sphingolipids depend-
ing on the method of preparation. Lipid rafts are  
related to the immiscibility of ordered and disor-
dered liquid microdomains in cells which cause  
decrease in free energy between two phases. Mem-
brane proteins are categorized based on their loca-
tion whether they are present in rafts or in liquid-
disordered phase or in the intermediate state. Thus, 
lipid rafts constitute proteins and lipids that not only 
.oat freely within the liquid disordered bilayer of 
cellular membranes but can also aggregate to form 
clusters. Removal of cholesterol which partitions  
between raft and non-raft phase makes the proteins 
non-functional. 
 Lipid rafts are also implicated in many viral and 
bacterial infections.13 For example, influenza virus 
and HIV-1 virus enter into the cell by binding at the 
rafts followed by altering the cell functions. In dis-
eases like HIV and leishmaniasis, pathogens inter-
fere with the function of rafts of the host cell and 
use them to gain entry into the cell interior.14 Apart 
from this the size of lipid raft is very important in 
raft-borne signaling proteins. They are in ‘off’ state 
when rafts are small and turned on when rafts  
aggregate to form clusters where functionally related 
proteins interact and signal transduction occurs. The 
size of a lipid raft can be anywhere between 10 nm 
to 1000 nm and they always restructure themselves 
by continuous forming and breaking. So it is quite 
difficult to study their evolution. 
8. Gene delivery 
According to Miller, gene therapy is defined either 
as ‘the use of genes as medicines to treat disease’ or 
‘the delivery of nucleic acid (with a vector) to  
patients for some therapeutic purpose.15’ In other 
words, it involves the delivery of the DNA to the 
targeted cells, thus curing the disease at its causative 
level. For this to be successful, an efficient delivery 
system should be available which transports the 
gene expression system into the cell that encodes a 
therapeutic protein that is either not produced in the 
patient or produced in a nonfunctional form. 
 The fact that naked DNA is not suitable for the in 
vivo transport of genetic materials into selected cell 
body types due to its degradation by serum nucle-
ases, search for efficient carrier system has intensi-
fied over the past few years. Vectors can be divided 
into two classes: viral or non-viral. Some of the viral 
vectors are adenovirus, retrovirus, adeno-associated 
virus, etc. However immunogenicity, toxicity, inser-
tional mutagenesis and vector inactivation, etc. have 
led the scientists to develop nonviral vectors. 
 Among non-viral vectors, DEAE-dextran medi-
ated transfection and calcium-phosphate methods 
are classical and popular methods. Now the research 
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is focused on the design and synthesis of, cationic 
lipids,16 cationic polymers17 and peptides which are 
highly efficient gene transfection vectors. Cationic 
liposomes or polymers bind to negatively charged 
DNA due to electrostatic interactions and form a 
complex. This binds to the cell surface and endocy-
tosis takes over. But after entering lysosome, there 
is no clear understanding as to how the release of 
DNA takes place before the occurrence of lysosomal 
degradation although the addition of bu.ering agents 
can reduce this to some extent. 
 Cationic lipids are converted into liposomes 
which contain inner aqueous pools capable of  
encapsulating drugs or DNA.16 Lipoplexes thus 
formed gain entry into the cell by slow endocytosis. 
The nucleic acids which escape from endosomal 
compartments enter into the cell cytoplasm. Nucleic 
acids may face further difficulty in entering the  
nucleus. Once it enters the nucleus, expression of 
delivered genes occurs. 
 Typically, a cationic lipid consists of a hydropho-
bic domain (usually two long aliphatic chains or 
cholesterol-type group), a cationic head group and a 
linker which connects these two parts. Many of the 
cationic lipids have glycerol backbone on which the 
hydrophobic tails are present.18 Even the head group 
is attached through a hydrophilic domain like poly-
ethylene glycol to impart special properties to the 
lipid. The systematic modification of each part and 
understanding of the structure activity relationship is 
an active area of research by many groups.19,20 
 There are many advantages of gene delivery by 
cationic lipids. Lipoplexes are easy to produce, they 
are non-immunogenic, can deliver large polynucleo-
tides into the cell. Ease of synthesis allows one to 
incorporate various functionalities to fine tune the 
efficiency. However, poor cell specific binding, low 
cellular uptake of plasmid DNA, serum incompati-
bility and toxicity are some of the issues that need to 
be addressed carefully in order to obtain an efficient 
cationic lipid for gene transfection. 
 Small interfering RNA (siRNA), sometimes 
known as short interfering RNA or silencing RNA, 
is a class of 20–25 nucleotide-long double stranded 
molecules that play a variety of roles in biology.21 
Most notably, siRNA is involved in the RNA inter-
ference (RNAi) pathway, where it interferes with the 
expression of a specific gene. It was observed that 
when double-stranded RNAs (ds-RNA) are injected 
into the worm Caenorhabditis elegans, genes, whose 
sequences were complementary to those of the  
introduced ds-RNAs were silenced.22 Now it is 
known that ds-RNAs are processed into short inter-
fering RNAs (siRNAs) by the RNase enzyme Dicer. 
These siRNAs are then incorporated into a silencing 
complex called RISC (RNA-induced silencing com-
plex), which identifies and silences complementary 
messenger RNAs.23 Delivery of siRNA directly in 
cells can be achieved by using microinjection, elec-
troporation or by the use of a transfection reagent. 
 In addition to their role in the RNAi pathway, 
siRNAs also act in RNAi-related pathways, e.g. as 
an antiviral mechanism or in shaping the chromatin 
structure of a genome. Also it has been shown that 
ds-RNAs targeting gene promoters induce potent 
transcriptional activation of associated genes and 
these are termed small activating RNAs (saRNAs). 
 The fact that RNAi via siRNAs can knock down 
any gene of interest, it has a great potential to con-
tribute to modern medicine.24 Because disease proc-
esses also depend on the activity of multiple genes, 
it is expected that in some situations turning off. the 
activity of a gene with a siRNA could produce a 
therapeutic benefit. There is also potential for using 
RNAi for the treatment of viral diseases such as 
those caused by the hepatitis C virus (HCV) and the 
human immunodeficiency virus (HIV). Synthetic 
siRNAs and expressed shRNAs have been used to 
target several early and late HIV-encoded RNAs in 
cell lines and in primary haematopoietic cells. When 
a hepatitis B virus (HBV) was co-delivered with an 
expression unit encoding an anti-HBV shRNA in 
mice, a significant knockdown (99%) of the HBV 
core antigen in liver hepatocytes could be achieved. 
Many studies have used siRNAs as an experimental 
tool to dissect the cellular pathways that lead to  
uncontrolled cell proliferation and to cancer. Thus 
RNAi has been proposed as a potential treatment for 
cancer. 
9. Challenges using siRNA technology 
Sometimes non-specific effects are triggered by the 
experimental introduction of a siRNA. A mammal-
ian cell may mistake siRNA as a viral by-product 
and mount an immune response. Off-targeting can 
also occur where the genes with incomplete com-
plementarity (microRNAs) are inadvertently down-
regulated by the siRNA and cause misinterpretation of 
data and toxicity. Introduction of too much siRNA 
can result in non-specific events due to activation of 
intrinsic immune responses. Thus intracellular  
delivery at therapeutically effective concentrations 
is yet to be achieved. 
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Figure 2. Schematic description of protein folding and inverse folding problems. (a) The 
protein folding problem deals with prediction of a protein three-dimensional structure from its 
amino acid sequence. (b) The inverse folding problem is to predict all possible sequences com-
patible with a given protein three-dimensional structure. 
 
 
 To derive maximum benefit from this emerging 
technology, strategies that maintain a high level of 
siRNA efficiency while minimizing the non-specific 
off-target effects associated with siRNA expression 
should be explored in detail. 
10. Protein therapeutics 
10.1 Folding and inverse folding problems 
Proteins are biopolymers that are typically com-
posed of 20 different kinds of monomer units 
(amino acids) linked by peptide bonds. Most pro-
teins fold into a well-defined three-dimensional 
structure. The structure of a protein is intimately 
linked to its function. For many proteins, the infor-
mation specifying the structure is encoded in the 
amino acid sequence. This can be shown by denatur-
ing purified protein in aqueous solution and allowing 
the protein to refold by removal of the denaturing 
agent. Although it is widely accepted that sequence 
specifies structure, it is still not possible to predict 
the structure of a protein from first principles given 
its amino acid sequence. This problem is known as 
the protein folding problem and it remains one of 
the major unsolved problems in biology. A related 
problem, known as the inverse folding problem has 
to do with enumeration of all possible sequences 
consistent with a given protein structure (figure 2). 
Solutions to this problem have important implica-
tions for protein design. Below we briefly describe 
progress in this area and applications to the design 
of biological therapeutic agents. 
 In proteins, bond lengths and bond angles be-
tween different types of atoms are highly conserved 
and depend only on the type of atom(s) involved, 
not the specific amino acid or protein. Differences in 
three dimensional structures between proteins arise 
primarily from differences in dihedral angles. This 
insight was made use of by Ramachandran and col-
leagues25 who showed that protein main chain con-
figurations are described by two dihedral angles  
(φ and ψ) and that substantial regions of conforma-
tional space are disallowed because of steric overlap 
Novel therapeutic strategies 
 
103
between non-bonded atoms. While Ramachandran 
and colleagues focused on steric restrictions  
imposed primarily by the main chain, protein struc-
tures are also constrained by side chain interactions. 
A major advance in addressing the inverse folding 
problem came from the work of Ponder and Rich-
ards.26 They demonstrated that approximating side 
chain conformations by discrete rotamers from a  
rotamer library, combined with a few additional 
constraints (avoidance of steric overlap, buried 
charge and large cavities) greatly restricted the 
number of sequences energetically compatible with 
a given main chain configuration/fold. One of the 
major challenges in inverse folding or protein design 
is addressing the combinational nature of the pro-
blem. For example, for a 100 residue protein, there 
are 20 possible amino acids at each position. If we 
assume that each amino acid on an average can be 
modeled by three rotameric configurations, there are 
still (20 × 3)100 i.e. ~10177 possible configurations 
that need to be sampled. A number of elegant ap-
proaches and approximations have been used27,28  
to reduce the search space and provide approximate 
solutions to the problem. A more tractable and com-
monly encountered problem is the structure based 
prediction of a limited number of mutations to alter 
specific properties of a protein. For example, muta-
tions to change protein stability or to modulate pro-
tein: protein or protein: substrate interactions. Major 
limitations in protein design arise from errors in the 
potential function(s) employed and the use of vari-
ous approximations and cut-offs to compute  
energies of specific sequence–structure combina-
tions. It is therefore essential to be able to experi-
mentally construct and test a large number of protein 
sequences and then experimentally select the opti-
mal ones from a large pool. There are a variety of 
methodologies for doing this, which include phage 
display, yeast display and ribosome display.29 
11. Antibodies as therapeutics 
The vast majority of therapeutics currently used to 
treat disease are small molecules with molecular 
weights of <500 Da.30 In recent years there have 
been increasing numbers of ‘biological’ therapeutics 
developed by the biotechnology industry. Mono-
clonal antibodies (mAbs) and related molecules con-
stitute the major fraction of protein therapeutics with 
2006 US sales of $14.5 billion31 and an annual 
growth rate >35%. However, the high cost of these 
treatments (of the order of Rs 100,000 per dose in 
some cases), have put them out of reach of the vast 
majority of people, especially in the developing 
world. It is therefore imperative to develop better 
and cheaper ways of developing and producing these 
molecules Antibodies (Abs) typically produced by 
the body in response to infection by a foreign agent 
are a complex mixture of molecular species, termed 
polyclonal antibodies. However, in 1975 Milstein 
and Kohler32 showed that large amounts of homoge-
nous antibody can be produced by fusion of an Ab 
producing cell with a myeloma cell. Since the Ab 
producing cell is typically from a mouse that has 
been immunized with the target protein (antigen), 
the resulting Abs need to be modified (humanized) 
before they can be used for therapeutic purposes in 
humans, as mouse derived Abs will provoke an  
immune response in humans. However, mouse  
derived Abs can be used without modification in  
diagnostic applications. Other drawbacks of conven-
tional hybridoma technology are that Abs cannot be 
raised against self molecules, toxins and some small 
molecules because of toxicity and/or lack of immu-
nogenicity. An alternative is the use of in vitro tech-
nology such as phage display or yeast surface 
display.29 
12. Antibody structure 
A schematic description of an immunoglobulin G 
(lgG) type Ab molecules is shown in figure 3. These 
constitute the major type of Ab in serum. The mole-
cule consists of a total of four polypeptide chains, 
two identical pairs of light chains and two identical 
pairs of heavy chains. Each light chain interacts with 
a single heavy chain through disulfide bonds and 
noncovalent interactions. The N terminal ~110 amino 
acids of each chain constitute the variable regions. 
Within the variable regions, maximal sequence  
diversity occurs within the so called complementarity 
determining regions (CDRs) which are directly  
involved in antigen binding. The CH2 region con-
tains a structurally and functionally important con-
served glycosylation site. In addition, there may be 
other nonconserved glycosylation sites in other  
regions of the molecule. The constant region (Fc) of 
an Ab is involved in effector functions which in-
volve binding to receptors (Fc receptors) on immune 
cells, such as natural killer (NK) cells or macro-
phages. Binding of multiple Abs to an antigen in  
vitro results in clustering of Fc regions and binding
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Figure 3. Antibody structure. (a) Schematic diagram of an immunoglobulin G type of Ab. 
Variable and constant domains are prefixed with V and C, respectively. The VH and VL vari-
able regions are involved in antigen binding. The Fc region involved in effector function con-
sists of the CH2 and CH3 domains. (b) Structure of mAb b12 (adapted from the pdbid 1HZH) 
using the program RASMOL (http://www.rasmol.org). Colours of the corresponding regions of 
(a) and (b) are identical. 
 
 
to Fc receptors, which in turn targets cells or parti-
cles displaying the antigen for destruction. In the 
following sections, we describe approaches that 
have been used to design and select therapeutic anti-
bodies (Abs) for use in humans and the possible use 
of similar technology for vaccine development. The 
first mAbs to be tested in humans were rodent de-
rived Abs developed by conventional hybridoma 
technology. However these suffered from several 
problems, such as low half-lives in humans, poor  
effector function and high immunogenicity (as they 
were recognized as foreign objects by the human 
immune system). More recently, these problems 
have been substantially addressed by the use of chi-
meric as well as humanized mAbs.33 Chimeric mAbs 
are ones in which the VH and VL chains are murine 
(mouse) derived, while the constant regions are of 
human origin. Such mAbs contain approximately 
33% of murine derived amino acid sequence. Hu-
manized mAbs contain only about 10% of murine 
sequence primarily in the hypervariable loops.  
Recent methodologies such as phage display of Ab 
libraries or transgenic mice with human immu-
noglobulin genes34,35 have made it possible to pro-
duce fully human mAbs (containing only human 
derived sequence) with desired specificities. It still 
remains to be shown whether fully human mAbs 
provide significant therapeutic benefit over chimeric 
or humanized mAbs.36 
13. Designer antibodies 
Protein design and selection methodology has been 
extensively used to modulate antigen binding, effec-
tor function and the in vitro half lives of mAbs and 
to design Ab fragments that retain one or more func-
tions of the intact molecule. The procedure for the in 
vitro selection of Abs from large libraries is summa-
rized in figure 4. For mAb libraries generated in vi-
tro, the diversity of the library can be generated 
either from synthetic variable genes or using vari-
able regions cloned from human B cells. During in 
vitro selections, the phenotype of the mAb displayed 
on a particle is linked to the genotype (DNA  
sequence encoding the mAb/fragment) which is 
packaged inside the particle (figure 4). The library 
consists of a large number of such particles (bacte-
riophages, viruses or cells). In one round of selec-
tion, the library is bound to immobilized antigen and 
unbound library members are washed off. Bound 
members are eluted, allowed to replicate in an  
appropriate host, re-purified and subjected to further 
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rounds of selection. At each round, the fraction of 
the input pool that binds is measured. Typically after 
a few rounds of selection, a significant fraction of  
the input pool shows binding. At this point individ-
ual members are sequenced, expressed, purified and 
characterized for binding affinity to the desired  
target. The diversity of libraries that can be screened 
in vitro is typically limited by the transformation  
efficiency of the host cell which is typically less 
than 109 transformants/μg of DNA. Since there are 
20 possible amino acids at each position, even a  
library where only 8 positions are randomized will 
have a diversity (208 = 256 × 108) in excess of what 
can be conveniently transformed. It is therefore im-
portant to use computational analyses to guide the 
choice of regions to be mutated as well as to intro-
duce specific types of diversity designed to simulate 
the types of amino acids that are abundant in natural 
binding sites.37 Recent studies have attempted to de-
fine the minimum diversity in amino acid sequence 
required for efficient recognition of antigens by 
mAbs. Eleven synthetic libraries were constructed 
with CDR diversity restricted to only four amino ac-
ids (including at least one small amino acid to pro-
vide conformational flexibility) and screened for 
binding to four different protein antigens. Two li-
braries (with amino acids Y/A/D/S and H/R/D/G) 
generated Abs against 3 of the 4 antigens.38 In an-
other study39 it was shown that functional Abs could 
be obtained with a diversity in CDR’s generated 
from only two amino acids (Y and S). High affinity 
(Kd =60 nM) and high specifity Abs against human 
vascular endothelial growth factor were obtained 
even with such a binary recognition code. 
 
 
 
 
Figure 4. Scheme for in vitro selection of Ab/Ab frag-
ments that bind to a given antigen. 
 In addition, to improving antigen binding affinity, 
protein design and selection strategies have also 
been used to improve Ab effector function. In a re-
cent study,40 automated protein design methodology 
combined with high throughput screening was used 
to engineer mutations in the Fc region of an anti-
CD52 mAb. The best of the designed variants 
showed an increase in effector function of over 100 
fold because of increased binding to the Fcγ RIIIa 
receptor. In another study41 the in vivo half of Abs 
and Ab fragments was modulated by mutations in 
the Fc region to alter interactions with the protective 
neonatal Fc receptor FcRn. This has both therapeutic 
and imaging applications. 
 One major barrier to the use of mAbs as therapeu-
tics is high cost. In part this is because they need to 
be expressed using expensive mammalian cell cul-
ture systems to ensure correct glycosylation. Re-
cently it has been possible to engineer yeast and 
other microbes to produce glycosylation patterns 
similar to those found in human cells42–45. These  
advances have the potential to dramatically lower 
costs of mAbs by expression in microbial systems. 
Alternative methods that can potentially lower costs 
of treatment are the use of genetically engineered 
cells for the continuous product of Abs in vivo.46 
14. Vaccine design 
As can be seen from the above discussion, the  
development of Ab therapeutics has been facilitated 
by a combination of developments in computational 
methodology for protein design, library construc-
tion, screening via phage/yeast display, development 
of appropriate transgenic mice and advances in un-
derstanding of factors modulating Ab efficiency in 
vitro. All the tools used in Ab design can also be  
applied to design better vaccines. In the developing 
world, infectious diseases are the leading cause of 
death. For three of the major infectious diseases 
(TB, malaria and HIV) no vaccine exists. For other 
diseases such as influenza, a satisfactory vaccine 
currently exists. However, the advent of highly 
pathogenic avian influenza (bird flu) and pandemic 
H1N1 is a reminder that new strategies to counter 
such newly emerging infections are urgently  
required. New approaches to vaccine design involve 
identification of the target antigen, followed by  
determination of its molecular structure as well as 
mapping regions of the structure (neutralization epi-
topes) where Ab binding will reduce or abrogate in-
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fectivity/pathogenicity. Following this, protein de-
sign methodology can be used to construct frag-
ments/domains of the protein containing the desired 
neutralization epitopes. The designed proteins can 
be screened for binding to known neutralizing 
mAbs. Selected molecules (immunogens) can be in-
jected in appropriate animal models to see if they 
can induce desired Ab responses and, where feasi-
ble, protect the animals from pathogenic challenge. 
Immunogens which show encouraging responses in 
small animals can be further tested in non-human 
primates and eventually in humans. This approach, 
known as ‘reverse vaccinology’ or ‘retrovaccinol-
ogy’47 has the potential to accelerate the develop-
ment of vaccines for emerging infections. It can also 
be used to reduce costs of existing vaccines, by re-
designing immunogens so that they can be expressed 
in microbial systems instead of currently used more 
expensive cell culture systems. However, further 
work needs to be done to assess the benefits of this 
methodology over conventional methods of using  
attenuated or killed versions of the infectious organ-
ism as vaccines. 
15. Conclusions 
Multitarget therapeutics as well as network analysis 
derived multicomponent therapeutics have the  
potential to treat diseases that have proved resistant 
to conventional single target therapeutics. Gene 
therapy and siRNA are alternatives to conventional 
drug treatment. Advances in gene delivery via cati-
onic lipids are important for the enormous potential 
benefits of gene therapy to be realized. Small mole-
cule drugs are by far, the most common allopathic 
therapeutics. However, the market for biological 
therapeutic proteins, especially antibodies and anti-
body derivatives is rapidly growing. Advances in 
computational biology, structural biology and im-
munology have led to the introduction of numerous 
mAb therapeutics in recent years. Improvements in 
protein design and screening methodologies have 
made it possible to modulate the stability, in vivo 
half-life and function of mAbs and similar molecules 
in a semi rational fashion. Similar methodologies can 
potentially be applied to design immunogens and 
vaccines for newly emerging global health threats. 
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